Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.

A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Calcium/Vitamin D Supplementation (Caltrate 600+ D) on Body Weight and Fat Loss in Overweight and Obese Individuals on a Weight-Reducing Program.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00353054

Enrollment

Registered

2006-07-17

Start date

2003-01-31

Completion date

2005-07-31

Last updated

2006-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

Keywords

Caltrate, Lipoproteins, Glucose, Insulin, Blood pressure, Body fat, Body weight, Women, Diet, Macronutrients

Brief summary

The aim of this study was to assess the effect of calcium/vitamin D supplementation (Caltrate 600 +D®) on body weight loss during a weight-reducing program

Detailed description

The effect of a calcium supplementation on body weight loss is inconclusive and some studies have suggested that adequate calcium intake can have a favourable effect on some metabolic variables. The objectives of this study were to evaluate the impact of (Caltrate 600 + D ®) on body composition and various indicators of metabolic health in overweight and obese females characterised by a usual low daily calcium intake, on a weight-reducing program. The main hypotheses of this study were: * Caltrate 600 +D® increases body weight and fat mass losses of individuals on a weight-reducing program. * Caltrate 600 +D® improves the metabolic profile of these subjects, independently of variations promoted by body fat loss.

Interventions

DRUGCaltrate® 600 + D

BEHAVIORALWeight loss intervention

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

30 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Daily calcium intake below 800mg/day * Stable body weight * Body mass index (BMI) between 27-40kg/m2 * Less than 3 periods of 20 minutes of physical exercise/week * General good health * Normal blood pressure values * Normal cholesterol levels * Normal thyroid hormone levels * No participation in another clinical trial within 6 months of screening * Coffee consumption ≤ 5 cups/day.

Exclusion criteria

* Breast feeding, pregnant or menopaused women * Use of calcium supplements within 30 days of screening * Cholesterol levels requiring pharmaceutical treatment * Smoking * Use of medication that could affect body weight

Design outcomes

Primary

Measure	Time frame
Body weight and fat mass loss at the end of the 15-week weight loss supplemented intervention.	—

Secondary

Measure	Time frame
Change in metabolic variables at the end of the 15-week calcium/vitamin D supplemented weight loss intervention	—
Change in energy/macronutrient intake at the end of the 15-week calcium/vitamin D supplemented weight loss intervention	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026